Developing new treatments for Alzheimer's Disease through medicinal chemistry
Official title: MCSP - EXPLORATORY CHEMISTRY (EC)
Funded at Albany Molecular Research, INC. · NIH-11062338 · Data updated 2026-11-12
This study is exploring new ways to create medications for Alzheimer's Disease that could help patients by targeting the specific processes involved in the condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albany Molecular Research, INC. NIH-funded |
| Lab location | 1 site (Albany, United States) |
| Project start | February 1, 2022 |
| Project end | February 1, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,388,544 |
| NIH project number | 271201800001I-P00002-759502200002-1 |
| Project ID | NIH-11062338 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's Disease or those at risk of developing it.
✕Less likely to help
Patients with other forms of dementia unrelated to Alzheimer's may not benefit from this research.
What this research studies
This research focuses on the early stages of drug development for Alzheimer's Disease, utilizing advanced medicinal chemistry techniques. The project aims to identify and design new compounds that can effectively target the biological processes involved in Alzheimer's. By employing structure-activity relationship (SAR) analysis and in vitro testing for absorption, distribution, metabolism, excretion, and toxicity (ADMET), the research seeks to discover novel therapeutic options. Patients may benefit from potential new treatments that arise from this innovative approach to drug discovery.
Why it matters
Potential benefit: If successful, this research could lead to new and effective treatments for Alzheimer's Disease, improving patient outcomes.
How similar studies have gone: Previous research in medicinal chemistry has shown promise in developing effective treatments for neurodegenerative diseases, indicating a potential for success in this area.
Where this research is happening
-
Albany Molecular Research, INC.
Albany, United States Active
Researchers
- Principal investigator: Barnes, Keith — Albany Molecular Research, INC.
- Study coordinator: Barnes, Keith
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.